This phase 2 FIGHT-207 basket study evaluated pemigatinib, an FGFR1-FGFR3 inhibitor, in patients with previously treated advanced solid tumors harboring FGFR alterations. Objective response rates (ORRs) were 26.5%, 9.4%, and 3.8% in cohorts A (fusions/rearrangements), B (activating non-kinase domain mutations), and C (kinase domain mutations), respectively. Median progression-free survival varied across cohorts. Common adverse events included hyperphosphatemia and stomatitis. TP53 co-mutations were associated with non-response, while BAP1 alterations correlated with higher response rates. Acquired resistance involved FGFR gatekeeper and molecular brake mutations. The study identified new therapeutic areas for FGFR inhibition and resistance mechanisms.

Jordi Rodón, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal